药明合联今日盘中大涨5.09%，引起了市场的广泛关注。
消息面上，公司此前披露的年度业绩表现强劲，成为推动股价上涨的主要动力。数据显示，公司实现收入59.44亿元人民币，同比增长46.6%，这主要得益于ADC等生物偶联CRDMO服务需求的拉动。同时，公司毛利率由30.6%显著提升至36.0%，年内溢利同比增长38.4%至14.80亿元人民币，显示出盈利能力的显著改善。
此外，今日生命科学工具和服务板块整体表现强势，板块联动效应明显。同板块的药明康德、康龙化成、昭衍新药及药明生物等公司股价均有不同程度上涨，市场情绪积极，进一步带动了药明合联的股价表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.